Trendlines portfolio company STS Medical receives FDA clearance for removable sinus stent

SINGAPORE (Jan 4): STS Medical, a portfolio company of The Trendlines Group, has received regulatory clearance from the US Food and Drug Administration (FDA) for its composite sinus stent which is designed to reduce the probability of revision surgeries after having undergone Functional Endoscopic Sinus Surgery (FESS).

FESS is often performed on people with chronic sinusitis to increase airflow within the nose and sinuses, improve drainage, and remove diseased tissue.

In a Wednesday announcement, Trendlines estimates that 30% of such FESS surgeries are unsuccessful due to scarring and recurrent inflammation that closes the nasal openings, hence requiring revision surgery.

---

Related Stories

• Trendlines expects proceeds of $8 mil if sale of portfolio company is completed
• Trendlines urges investors to focus on long-term growth, not lumpy earnings
• The Trendlines Group – from seed to market

---